Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics of JT001 (VV116) for the early Treatment of Coronavirus Disease 2019 (COVID-19) in participants with mild to moderate COVID-19, at high risk for progression to severe COVID-19, including death.


Clinical Trial Description

Screening Interested participants will sign the appropriate informed consent form (ICF) prior to completion of any study procedures. The investigator will review symptoms, risk factors and other non-invasive inclusion and exclusion criteria prior to any invasive procedures. If the participant is eligible after this review, then the site will perform the invasive procedures to confirm eligibility. Treatment and Assessment Period - Complete baseline procedures and sample collection - Participants are randomized to an intervention group - Participants receive study intervention (Q12H X 5 days) - Complete all safety monitoring - Complete all efficacy data collection - Blood samples collection ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05242042
Study type Interventional
Source Shanghai JunTop Biosciences Co., LTD
Contact
Status Terminated
Phase Phase 2/Phase 3
Start date January 28, 2022
Completion date March 23, 2023

See also
  Status Clinical Trial Phase
Withdrawn NCT04705844 - Study of Adalimumab or Placebo in Patients With Mild to Moderate COVID-19 (COMBAAT) Phase 3
Recruiting NCT05941793 - A Study to Evaluate the Efficacy, Safety, and Concentration of SNS812 in Mild to Moderate COVID-19 Patients Phase 2
Terminated NCT04521296 - Efficacy and Safety of DWJ1248 in Patients With Mild to Moderate COVID-19 Compared to the Placebo Phase 2/Phase 3
Completed NCT05582629 - JT001 (VV116) for the Treatment of COVID-19 Phase 3
Completed NCT05620160 - Study of RAY1216 Tablets Compared With Placebo in Patients With Mild to Moderate COVID-19 Phase 3
Completed NCT06197217 - Phase III Clinical Study Evaluating the Efficacy and Safety of WPV01 in Patients With Mild/Moderate COVID-19 Phase 3
Recruiting NCT05675072 - Evaluate the Efficacy and Safety of FB2001 for Inhalation in Patients With Mild to Moderate COVID-19 Phase 2/Phase 3
Suspended NCT04711863 - Fluvoxamine for Adults With Mild to Moderate COVID-19 Phase 2